Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20452156 | 1.00 | CCR6 (0.54) | CCR6 | |
| SCHEMBL1706013 | 0.90 | CCR6 (0.50) | CCR6 | |
| SCHEMBL14007565 | 0.89 | CCR6 (0.49) | CCR6 | |
| SCHEMBL1705775 | 0.89 | CCR6 (0.49) | CCR6 | |
| SCHEMBL1706003 | 0.88 | CCR6 (0.51) | CCR6 | |
| SCHEMBL14136746 | 0.86 | CXCR2 (0.49) | CCR6 | |
| SCHEMBL1705871 | 0.86 | CXCR2 (0.52) | CCR6 | |
| SCHEMBL1706485 | 0.85 | CCR6 (0.64) | CCR6 | |
| SCHEMBL1705955 | 0.85 | CCR6 (0.54) | CCR6 | |
| SCHEMBL1706337 | 0.84 | CCR6 (0.56) | CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | SYNTRIX BIOSYSTEMS INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180235964-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| WO-2010063802-A1 | 3, 4-DI-SUBSTITUTED CYCLOBUTENE- 1, 2 -DIONES AS CXCR2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235964-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | CXCR1, CXCR2, CXCR6 | CCR6 20/4885 |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CCR6 20/4885 |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | CXCR1, CXCR2, CXCR6 | CCR6 20/4885 |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | CXCR1, CXCR2, FPR2 | CCR6 30/4885 |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | CXCR1, CXCR2, CXCR5 | CCR6 19/4885 |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | CXCR1, CXCR2, CXCR5 | CCR6 19/4885 |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CCR6 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.